Would you consider OFS in a young patient (<35) with ER+ breast cancer who required chemotherapy and menses resumed years later while on tamoxifen?

The SOFT/TEXT trial demonstrated a DFS/OS benefit for OFS when added to endocrine therapy. Patients at higher risk (<35 years old, node +, treated with chemotherapy) would likely benefit more. The decision to do this depends on her baseline risk. The HER2 status is interesting in that HER2- patients...

The survival benefit for OS is among LN + patients, not LN-. So, it would depend on clinical risk and nodal status for me. If she is node negative, odds are she will not get substantial benefit over tamoxifen alone.